ClinicalTrials.gg
TerminatedNCT05276830Updated Aug 11, 2026Results posted

An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia

A Phase 2 interventional study of BXCL501 and BXCL501 in Agitation and Dementia, sponsored by BioXcel Therapeutics Inc. Terminated at 3 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by BioXcel Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was terminated for business reasons; not due to safety or efficacy concerns

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.

Enrollment
30th of 32
5 · median 73
Started
2022
with 4 others
Phase 2
6 of 32
none open now
Registered
22nd of 32
by date
Lead sponsor
11 of 32
BioXcel Therapeutics Inc

Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one is the 30th largest by enrollment, is one of 5 that started in 2022, is one of 6 in phase 2, and was the 22nd registered.

Psychomotor Agitation

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

Browse Psychomotor Agitation studies →

Open to participants now

5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing dexmedetomidine in Psychomotor Agitation, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.

Read the detailed description

The study will enroll at least 75 subjects to receive a single film consisting of BXCL501 40 μg dose, BXCL501 60 μg dose, or matching placebo film. Subjects must reside in a residential care facility and must require at least moderate assistance with activities of daily living (e.g., bathing, dressing, and toileting). The subject must be able to self-administer the film to participate in the study.

The effects of BXCL 501 on acute agitation will be assessed by the following scales: PEC, PAS, ACES, and CGI-I.

03

Conditions studied

  • Agitation
  • Dementia
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Individuals diagnosed with any form of dementia (i.e., probable Alzheimer's Disease; vascular dementia; mixed; frontotemporal dementia)
  2. Subjects who have met criteria for dementia (major neurocognitive disorder) who have instances of acute psychomotor agitation.
  3. History of psychomotor agitation (e.g., kick, bite, flailing) to the point that it impairs social activities, requires staffing, or medical intervention, or impairs ability for functional activities of daily living.
  4. Subjects are expected to exhibit behaviors that are congruent with the International Psychogeriatric Association criterion for agitation representing a change from the subject's usual behavior.
  5. Subjects who have a score of ≤16 on the (MMSE).
  6. Subjects with a remote (>5 years) history of stroke may be included, regardless of size/location.
  7. Subjects who read, understand, and provide written , or who have a legally authorized representative (LAR).
  8. Subjects who are deemed to be medically appropriate for study participation by the principal investigator.
  9. Subjects who are at their current location for at least 14 days before screening and plan to remain at the same location for the duration of the study.
  10. Subjects who have the capability to participate in the study and self-administer the product.
  11. Subjects who are on a stable concomitant medications regimen for the treatment of any concurrent conditions for at least one month prior to the screening visit.

Exclusion criteria

Exclusion Criteria:

  1. Subjects who have dementia associated with Parkinson's disease and/or Lewy Body Disease are excluded.
  2. Subjects suffering from alcohol and/or substance abuse.
  3. Subjects with agitation caused by acute intoxication must be excluded.
  4. Subjects with significant risk of suicide or homicide per the investigator's assessment.
  5. Subjects who have hydrocephalus, seizure disorder, or history of significant head trauma, subarachnoid bleeding, brain tumor, encephalopathy, meningitis, or focal neurological findings, with a recent (1 year) large (non-microvascular) stroke who may be considered medically unstable or in recovery must be excluded.
  6. History of syncope or syncopal attacks, orthostatic hypotension within the past 2 years.
  7. Subjects with laboratory or abnormalities.
  8. Subjects with serious, unstable, or uncontrolled medical illnesses must be excluded.
  9. Subjects who have received an drug within 30 days prior to Screening must be excluded.
  10. Subjects who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving dexmedetomidine must be excluded.
  11. Subjects whose agitation is attributed to pain or infection, delirium, concomitant medications, environmental conditions, or another psychiatric condition or medical condition as determined by the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    40 micrograms

    Sublingual film containing 40 micrograms Dexmedetomidine

    Drug: BXCL501

  • Experimental
    60 micrograms

    Sublingual film containing 60 micrograms Dexmedetomidine

    Drug: BXCL501

  • Experimental
    Placebo

    Sublingual Placebo film

    Drug: Placebo film

Interventions

  • Sublingual film containing 40 Micrograms BXCL501

    Also known as: Dexmedetomidine

  • Sublingual film containing 60 Micrograms BXCL501

    Also known as: Dexmedetomidine

  • DrugPlacebo film

    Matching Sublingual Placebo film

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

    The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe).

    Time frame: 120 minutes

Secondary outcomes

  1. Change From Baseline for Pittsburgh Agitation Scale

    The Pittsburgh Agitation Scale (PAS) assesses agitation for individuals with dementia across four behavior groups: aberrant vocalizations, motor agitation, aggressiveness, and resisting care. Each behavior group is scored ranging from 0 (not present) to 4 (maximally present).

    Time frame: 120 minutes

  2. Change From Baseline for Agitation-Calmness Evaluation Scale

    The Agitation-Calmness Evaluation Scale (ACES) is a single item measure rating overall agitation and sedation, where 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable

    Time frame: 120 minutes

  3. Clinical Global Impression - Improvement

    The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

    Time frame: 120 minutes

07

Results

Posted Aug 25, 2023
Limitations and caveats
The study was terminated prematurely due to business reasons. There were no Safety or Efficacy Concerns.

Participant flow

The study was conducted in United States from 08 February 2022 to 01 April 2022.

Participant flow — Overall Study
MilestoneBXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlacebo
Started212
Completed212
Not completed000

Outcome measures

PrimaryChange in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score

The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe).

Time frame:
120 minutes

No measurements were reported for this outcome.

SecondaryChange From Baseline for Pittsburgh Agitation Scale

The Pittsburgh Agitation Scale (PAS) assesses agitation for individuals with dementia across four behavior groups: aberrant vocalizations, motor agitation, aggressiveness, and resisting care. Each behavior group is scored ranging from 0 (not present) to 4 (maximally present).

Time frame:
120 minutes

No measurements were reported for this outcome.

SecondaryChange From Baseline for Agitation-Calmness Evaluation Scale

The Agitation-Calmness Evaluation Scale (ACES) is a single item measure rating overall agitation and sedation, where 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable

Time frame:
120 minutes

No measurements were reported for this outcome.

SecondaryClinical Global Impression - Improvement

The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

Time frame:
120 minutes

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 to Day 7. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BXCL501: 40 Micrograms0/2 (0%)0/2 (0%)1/2 (50%)
BXCL501: 60 Micrograms0/1 (0%)0/1 (0%)1/1 (100%)
Placebo0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Most frequent other events
EventBXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlacebo
SomnolenceNervous system disorders1/21/10/2
Urinary tract infectionInfections and infestations0/21/10/2
BradycardiaCardiac disorders0/21/10/2
NauseaGastrointestinal disorders1/20/10/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)BXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlaceboTotal
<=18 years0000
Between 18 and 65 years0000
>=65 years2125
Sex: Female, Male
Sex: Female, Male(Participants)BXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlaceboTotal
Female1102
Male1023
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlaceboTotal
Hispanic or Latino1001
Not Hispanic or Latino1124
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BXCL501: 40 MicrogramsBXCL501: 60 MicrogramsPlaceboTotal
Caucasian2103
Black or African American0022
08

Study locations

3 sites
  • Bioxcel Clinical Research Site
    North Miami, Florida 33161, United States
  • Bioxcel Clinical Research Site
    Springfield, Massachusetts 01103, United States
  • BioXcel Clinical Research Site
    Toms River, New Jersey 08755, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2022 to primary completion in Apr 2022, 1 month.

Results were first posted in Aug 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2022
First posted
Mar 11, 2022
StartActual
Feb 8, 2022
Primary completionActual
Apr 1, 2022
CompletionActual
Apr 1, 2022
Results first posted
Aug 25, 2023
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05276830
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Cognitive Research Corporation
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Feb 8, 2022
Primary completion
Apr 1, 2022
Completion
Apr 1, 2022
Results posted
Aug 25, 2023
Last update
Aug 11, 2026

Study contacts

BioXcel MM, MD
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion